✦ LIBER ✦

Mitoxantrone in the treatment of relapsed and refractory acute leukemia

✍ Scribed by P. Meyer; A. D. Ho; G. Ehninger; I. Mjaaland; E. Heidemann; E. Seither

Publisher: Springer US
Year: 1985
Tongue: English
Weight: 245 KB
Volume: 3
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00174171

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone| dihydroxyanthracenedione) was administered in a dose of 8-13 mg/m 2 on five consecutive days. Five of 20 evaluable patients were induced into complete remission, one patient achieved a partial remission. Side-effects included moderate to severe bone marrow suppression, moderate mucositis and hair loss. No cardiotoxicity was observed. We believe that mitoxantrone is an active agent in the treatment of acute leukemia and suggest further studies in combination chemotherapy.

📜 SIMILAR VOLUMES

Mitoxantrone for refractory and relapsed

Mitoxantrone for refractory and relapsed acute leukemia

✍ Werner R. Bezwoda; Cano Bernasconi; Robert M. Hutchinson; David A. Winfield; Rob 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB 👁 2 views

Mitoxantrone in relapsed or refractory a

Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia

✍ Vredenburgh, James J. ;McLntyre, O. Ross ;Cornwell, Gibbons G. ;Ball, Edward D. 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB

Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days. If the day fourteen bone marrow showed residual leukemia, a second course was given at the same dose for two days. Eight patient

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I study

✍ Philip C. Amrein; Roger B. Davis; Robert J. Mayer; Charles A. Schiffer 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

Treatment of relapsed or refractory adul

Treatment of relapsed or refractory adult acute lymphocytic leukemia

✍ Mathias Freund; Helmut Diedrich; Arnold Gamer; Martin Gramatzki; Gerhard Heil; A 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

Mitoxantrone and high-dose etoposide for

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia

✍ Susan O'Brien; Kantarjian Hagop; Elihu Estey; Charles Koller; Miloslav Beran; Ke 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Continuous infusion mitoxantrone in rela

Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia

✍ Lynne S. Kaminer; Kyung E. Choi; Karen M. Daley; Richard A. Larson 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 2 views

Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia. The authors' goal was to treat patients with continuous infusion mitoxantrone in order to maintain cytotoxic steady state levels with acceptable toxicity and to assess the results. Daily mitoxantrone